Gina M. Sequeira

Gina M. Sequeira

Auto-generated profile, based on publicly available information

Gina M. Sequeira

Seattle Children’s Hospital, Seattle, Washington, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Journal of Adolescent Health
Verified
Journal Article
Closed access
GSGina M. Sequeira
Gina M. Sequeira
KKKacie M. Kidd
Kacie M. Kidd
RCRobert W.S. Coulter
Robert W.S. Coulter
EMElizabeth Miller
Elizabeth Miller
DFDennis Fortenberry
Dennis Fortenberry
KRKristin N. Ray
Kristin N. Ray

20 February 2020 in Journal of Adolescent Health
Verified
Journal Article
Closed access
GSGina M. Sequeira
Gina M. Sequeira
KRKristin N. Ray
Kristin N. Ray
EMElizabeth Miller
Elizabeth Miller
RCRobert W.S. Coulter
Robert W.S. Coulter

10 August 2022 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
AVAnna Valentine
Anna Valentine
SDShanlee Davis
Shanlee Davis
AFAnna Furniss
Anna Furniss
NDNadia Dowshen
Nadia Dowshen
AKAnne E Kazak
Anne E Kazak
NNNatalie Nokoff
Natalie Nokoff
Context: Studies on cardiometabolic health in transgender and gender-diverse youth (TGDY) are limited to small cohorts. Objective: This work aimed to determine the odds of cardiometabolic-related diagnoses in TGDY compared to matched controls in a cross-sectional analysis, using a large, multisite database (PEDSnet). Methods: Electronic health record data (2009-2019) were used to determine odds of cardiometabolic-related outcomes based on diagnosis, anthropometric, and laboratory data using logistic regression among TGDY youth vs controls. The association of gender-affirming hormone therapy (GAHT) with these outcomes was examined separately among TGDY. TGDY (n = 4172) were extracted from 6 PEDSnet sites and propensity-score matched on 8 variables to controls (n = 16 648). Main outcomes measures included odds of having cardiometabolic-related diagnoses among TGDY compared to matched controls, and among TGDY prescribed GAHT compared to those not prescribed GAHT. Results: In adjusted analyses, TGDY had higher odds of overweight/obesity (1.2; 95% CI, 1.1-1.3) than controls. TGDY with a testosterone prescription alone or in combination with a gonadotropin-releasing hormone agonist (GnRHa) had higher odds of dyslipidemia (1.7; 95% CI, 1.3-2.3 and 3.7; 95% CI, 2.1-6.7, respectively) and liver dysfunction (1.5; 95% CI, 1.1-1.9 and 2.5; 95% CI, 1.4-4.3) than TGDY not prescribed GAHT. TGDY with a testosterone prescription alone had higher odds of overweight/obesity (1.8; 95% CI, 1.5-2.1) and hypertension (1.6 95% CI, 1.2-2.2) than those not prescribed testosterone. Estradiol and GnRHa alone were not associated with greater odds of cardiometabolic-related diagnoses. Conclusion: TGDY have increased odds of overweight/obesity compared to matched controls. Screening and tailored weight management, sensitive to the needs of TGDY, are needed.

1 April 2022 in Transgender Health
Verified
Journal Article
Closed access
GSGina M. Sequeira
Gina M. Sequeira
KKKacie M. Kidd
Kacie M. Kidd
JRJacquelin Rankine
Jacquelin Rankine
EMElizabeth Miller
Elizabeth Miller
KRKristin N. Ray
Kristin N. Ray
LRLaura P. Richardson
Laura P. Richardson
Purpose: Telemedicine holds potential to improve access to gender-affirming care for gender-diverse youth (GDY), but little is known about youth's perspectives regarding its use. The purpose of this study was to explore GDY's experiences and satisfaction with telemedicine for gender-affirming care during the COVID-19 pandemic. Methods: An online, cross-sectional survey was completed by 12–17-year-old GDY after a telemedicine gender clinic visit. Demographic characteristics, responses to a 12-item telemedicine satisfaction scale, and items assessing interest in future telemedicine use were analyzed using descriptive statistics. Open-ended items exploring GDY's experiences were coded qualitatively to identify key themes. Results: Participants' ( n =57) mean age was 15.6 years. A majority were satisfied with telemedicine (85%) and willing to use it in the future (88%). Most GDY preferred in-person visits for their first gender care visit (79%), with fewer preferring in-person for follow-up visits (47%). Three key themes emerged from the open-ended comments: (1) benefits of telemedicine including saving time and feeling safe; (2) usability of telemedicine such as privacy concerns and technological difficulties; and (3) telemedicine acceptability, which included comfort, impact on anxiety, camera use, and patient preference. Conclusions: Despite their preference for in-person visits, a majority of GDY were satisfied and comfortable with telemedicine, and expressed their interest in continuing to have telemedicine as an option for care. Pediatric gender care providers should continue services through telemedicine while implementing protocols related to privacy and hesitation regarding camera use. While adolescents may find telemedicine acceptable, it remains unclear whether telemedicine can improve access to gender-affirming care.

1 May 2020 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
GSGina M. Sequeira
Gina M. Sequeira
KKKacie Kidd
Kacie Kidd
RCRobert W. S. Coulter
Robert W. S. Coulter
EMElizabeth Miller
Elizabeth Miller
Robert GarofaloRobert Garofalo
Robert Garofalo
KRKristin N. Ray
Kristin N. Ray
Transgender youths experience significant health disparities compared with their cisgender peers. Recent data suggest that use of gender-affirming language, specifically name and pronouns, in more life contexts is associated with improved mental health outcomes.1

16 September 2021 in The Journal of Pediatrics
Verified
Journal Article
Closed access
GSGina M. Sequeira
Gina M. Sequeira
TBTaylor Boyer
Taylor Boyer
RCRobert W.S. Coulter
Robert W.S. Coulter
EMElizabeth Miller
Elizabeth Miller
NKNicole F. Kahn
Nicole F. Kahn
KRKristin N. Ray
Kristin N. Ray